Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.
Parisi S, Ruggeri L, Dan E, Rizzi S, Sinigaglia B, Ocadlikova D, Bontadini A, Giudice V, Urbani E, Ciardelli S, Sartor C, Cristiano G, Nanni J, Zannoni L, Chirumbolo G, Arpinati M, Lewis RE, Bonifazi F, Marconi G, Martinelli G, Papayannidis C, Paolini S, Velardi A, Cavo M, Lemoli RM, Curti A. Parisi S, et al. Among authors: nanni j. Front Immunol. 2022 Jan 31;12:804988. doi: 10.3389/fimmu.2021.804988. eCollection 2021. Front Immunol. 2022. PMID: 35173709 Free PMC article.
Acute Myeloid Leukemia Mutations: Therapeutic Implications.
Papayannidis C, Sartor C, Marconi G, Fontana MC, Nanni J, Cristiano G, Parisi S, Paolini S, Curti A. Papayannidis C, et al. Among authors: nanni j. Int J Mol Sci. 2019 Jun 3;20(11):2721. doi: 10.3390/ijms20112721. Int J Mol Sci. 2019. PMID: 31163594 Free PMC article. Review.
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Marconi G, Talami A, Abbenante MC, Sartor C, Parisi S, Nanni J, Bertamini L, Ragaini S, Olivi M, de Polo S, Cristiano G, Fontana MC, Bochicchio MT, Ottaviani E, Arpinati M, Sessa M, Baldazzi C, Caso L, Testoni N, Baccarani M, Bonifazi F, Martinelli G, Paolini S, Cavo M, Papayannidis C, Curti A. Marconi G, et al. Among authors: nanni j. Eur J Haematol. 2020 Jul;105(1):47-55. doi: 10.1111/ejh.13406. Epub 2020 Apr 7. Eur J Haematol. 2020. PMID: 32145118
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
Marconi G, De Polo S, Martinelli G, Nanni J, Bertamini L, Talami A, Olivi M, Ragaini S, Abbenante MC, Sartor C, Ottaviani E, Bochicchio MT, Parisi S, Fontana MC, Cristiano G, Raffini M, Baldazzi C, Testoni N, Bonifazi F, Paolini S, Curti A, Cavo M, Papayannidis C. Marconi G, et al. Among authors: nanni j. Leuk Res. 2021 Feb;101:106497. doi: 10.1016/j.leukres.2020.106497. Epub 2020 Dec 25. Leuk Res. 2021. PMID: 33385697 Clinical Trial.
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.
Fontana MC, Nanni J, Ghelli Luserna di Rorà A, Petracci E, Padella A, Ghetti M, Ferrari A, Marconi G, Soverini S, Iacobucci I, Papayannidis C, Curti A, Audisio E, Giannini MB, Rondoni M, Lanza F, Cavo M, Martinelli G, Simonetti G. Fontana MC, et al. Among authors: nanni j. Biomedicines. 2021 Apr 6;9(4):388. doi: 10.3390/biomedicines9040388. Biomedicines. 2021. PMID: 33917342 Free PMC article.
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
Papayannidis C, Sartor C, Dominietto A, Zappone E, Arpinati M, Marconi G, Cristiano G, Nanni J, Parisi S, Barbato F, Paolini S, Soverini S, Terragna C, Robustelli V, Testoni N, Chirumbolo G, Curti A, Cavo M, Bonifazi F. Papayannidis C, et al. Among authors: nanni j. Hematol Oncol. 2021 Oct;39(4):580-583. doi: 10.1002/hon.2886. Epub 2021 May 7. Hematol Oncol. 2021. PMID: 33963566 No abstract available.
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
Simonetti G, Mengucci C, Padella A, Fonzi E, Picone G, Delpino C, Nanni J, De Tommaso R, Franchini E, Papayannidis C, Marconi G, Pazzaglia M, Perricone M, Scarpi E, Fontana MC, Bruno S, Tebaldi M, Ferrari A, Bochicchio MT, Ghelli Luserna Di Rorà A, Ghetti M, Napolitano R, Astolfi A, Baldazzi C, Guadagnuolo V, Ottaviani E, Iacobucci I, Cavo M, Castellani G, Haferlach T, Remondini D, Capozzi F, Martinelli G. Simonetti G, et al. Among authors: nanni j. Leukemia. 2021 Oct;35(10):2813-2826. doi: 10.1038/s41375-021-01318-x. Epub 2021 Jun 30. Leukemia. 2021. PMID: 34193978 Free PMC article.
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia.
Ragaini S, Wagner S, Marconi G, Parisi S, Sartor C, Nanni J, Cristiano G, Talami A, Olivi M, Ocadlikova D, Ciciarello M, Corradi G, Ottaviani E, Papayannidis C, Paolini S, Vadakekolathu J, Cavo M, Rutella S, Curti A. Ragaini S, et al. Among authors: nanni j. Blood Adv. 2022 Jan 11;6(1):87-99. doi: 10.1182/bloodadvances.2021004878. Blood Adv. 2022. PMID: 34535017 Free PMC article.
34 results